Goldman Sachs & Co., TD Cowen, Leerink Partners, and JMP Securities are managing the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGMT:
- Sagimet Biosciences Stock (NASDAQ:SGMT): Don’t Get Squeezed Out of Your Money
- Sagimet Biosciences price target raised to $47 from $31 at JMP Securities
- Sagimet Biosciences Inc trading resumes
- Sagimet Biosciences Inc trading halted, volatility trading pause
- Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH